Mixed connective tissue disease: the AU general practice guide

What MCTD is and who develops it

Mixed connective tissue disease (MCTD) — sometimes called Sharp’s syndrome after the physician who first described it in 1972 — sits at an unusual intersection of clinical medicine. Rather than fitting neatly into systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or polymyositis/dermatomyositis, it blends features of all three, unified by a single defining antibody: high-titre anti-U1-RNP.

MCTD is rare but clinically important. Epidemiological data estimate prevalence at approximately 3.8–10 per 100,000, equating to roughly 1 in 10,000 Australians — under-recognised in general practice. The condition is strikingly female-predominant (9:1 female-to-male ratio) with peak onset in the 30s, although the age range spans childhood to late adulthood. There is no strong ethnic predilection, though Norwegian and Japanese cohorts show modestly higher prevalence.

Raynaud’s phenomenon and puffy, oedematous hands are typically the first recognisable features, sometimes appearing years before the full diagnostic picture emerges. GPs who keep MCTD in the differential when a woman in her 30s presents with Raynaud’s and swollen fingers will detect it earlier, before the pulmonary complications that dominate long-term prognosis develop.

A. Core clinical — the AU general practice framework

Diagnosis

MCTD is classified using serological and clinical criteria. Alarcón-Segovia 1989 is the most widely validated and preferred in Australian practice (eTG Rheumatology; Alarcón-Segovia 1989):

• Serological criterion (mandatory): Anti-U1-RNP at titre ≥1:1,600 by haemagglutination.
• Plus three or more of five clinical criteria: oedema of hands (“puffy hands”); synovitis; biologically or histologically confirmed myositis; Raynaud’s phenomenon; acrosclerosis (sclerodactyly).

Sensitivity is ~63%, specificity ~86%. The Kahn 1991 criteria are more sensitive and useful for early disease; the Sharp 1987 criteria are more specific but operationally complex.

ANA and ENA panel is the GP’s first-line serology: almost 100% of MCTD patients are ANA-positive with a high-titre speckled pattern. The RACGP recommends ENA panel including anti-U1-RNP, anti-Sm, anti-dsDNA, anti-Scl-70, anti-centromere, anti-Ro/La, anti-Jo-1, and anti-RNA pol III in any patient with suspected MCTD or overlap CTD. A strongly positive ANA with a high-titre speckled pattern in a woman with Raynaud’s and puffy hands warrants urgent ENA panel.

History to take

• Raynaud’s onset and severity — frequency, colour changes, asymmetry, digital ulcers, onset before other features.
• Puffy hands and morning stiffness — duration of early-morning stiffness, joint swelling, small and large joints.
• Proximal muscle weakness — difficulty climbing stairs, brushing hair, rising from a chair.
• Dyspnoea and cough — at every visit, any change from baseline (ILD and PAH screen).
• Swallowing and reflux — dysphagia, heartburn, regurgitation (oesophageal dysmotility).
• Sicca symptoms — dry eyes, dry mouth, dyspareunia, dental caries (Sjögren’s overlap).
• Photosensitive rash, oral ulcers, alopecia, telangiectasiae.
• Neurological — trigeminal neuralgia (classic), peripheral sensory symptoms, cognitive dysfunction.
• Renal — frothy urine, oedema, hypertension.
• Obstetric history — pregnancy loss at ≥10 weeks, preterm pre-eclampsia, neonatal heart block.
• Medication history — full review including over-the-counter and complementary therapies.
• Occupation and environment — silica or organic solvent exposure.

Examination

• Hands — puffy oedema, sclerodactyly (note proximal extent), digital ulcers or pitting, periungual erythema, dilated nailfold capillaries visible with a dermoscope.
• Skin — malar rash, telangiectasiae, livedo, alopecia, photosensitive distribution, calcinosis.
• Joints — active synovitis (warmth, effusion), Jaccoud-pattern deformity (reducible), tenosynovitis.
• Muscle — proximal weakness testing (deltoid, hip flexor MRC grade), tenderness.
• Cardiopulmonary — fine basal crackles (ILD), loud P2 with RV heave and raised JVP (PAH), pericardial friction rub.
• Blood pressure both arms — screen for scleroderma renal crisis pattern.
• Neurological — peripheral sensory examination, trigeminal sensory testing.

Initial investigations

Per eTG Rheumatology and Reiseter 2018, the initial GP panel for any suspected MCTD or overlap CTD includes:

• ANA with HEp-2 IF titre + ENA panel (anti-U1-RNP defining).
• Anti-dsDNA, RF + anti-CCP, complement C3 and C4.
• FBC, ESR, CRP, UEC, LFT, CK (fasting morning sample preferred).
• Lipids, HbA1c, vitamin D, TFT.
• Urinalysis + urine albumin:creatinine ratio (proteinuria, dysmorphic RBCs).
• Antiphospholipid panel (lupus anticoagulant, aCL IgG/IgM, anti-β2GP1).
• Hepatitis B surface antigen, hepatitis C antibody, and HIV serology — pre-immunosuppression baseline.

Pulmonary surveillance at diagnosis and annually:

• High-resolution CT (HRCT) chest — ILD pattern and extent.
• Pulmonary function tests — FVC, FEV1, TLC, and DLCO — restrictive defect with reduced DLCO is sensitive for ILD; DLCO below 60% predicted flags PAH risk.
• Six-minute walk test — desaturation flag.
• Echocardiogram with estimated pulmonary artery systolic pressure (PASP) and RV function — PAH screen per the DETECT algorithm.

B. Evidence appraisal — ILD, PAH, and disease classification

ILD — the dominant mortality driver

Interstitial lung disease affects approximately 50% of patients with MCTD over long-term follow-up (Reiseter et al. 2018). The typical pattern on HRCT is non-specific interstitial pneumonia (NSIP), which shows basal predominant ground-glass opacity, traction bronchiectasis, and reticulation — a more favourable pattern than the usual interstitial pneumonia (UIP) associated with idiopathic pulmonary fibrosis.

The strongest evidence for pharmacological management comes from the SLS-II trial (Tashkin et al. Lancet Respir Med 2016) in SSc-ILD, which showed mycophenolate mofetil (MMF) non-inferior to oral cyclophosphamide at 24 months for FVC with better tolerability. This evidence is reasonably extrapolated to MCTD-ILD in Australian practice (eTG; ARA), making MMF the standard first-line immunosuppressant for MCTD-ILD.

PAH — the second mortality driver

Pulmonary arterial hypertension affects approximately 25% of MCTD patients over long-term follow-up and is the single largest contributor to mortality in 30-year cohorts (Hajas et al. 2013). PAH in MCTD is often insidious — presenting with fatigue and mildly reduced exercise tolerance before more florid right heart failure develops. Annual echocardiogram with PASP estimation is the minimum surveillance; echocardiographic PASP above 40 mmHg or unexplained DLCO drop warrants specialist respiratory and cardiology referral for right heart catheterisation to confirm the diagnosis before PAH-specific therapy is initiated.

MCTD versus UCTD — when does it matter?

Mosca et al. 2011 defined UCTD as early autoimmune features insufficient for any definite CTD for at least 12 months. Approximately 30% of UCTD patients progress to a definite CTD within five years (most commonly SLE, followed by SSc and MCTD); 50% remain UCTD long-term; 10–20% remit. Stable UCTD has a far more favourable prognosis than definite MCTD. This distinction shapes surveillance: UCTD warrants annual review and targeted autoantibody re-testing, but not the intensive pulmonary surveillance of confirmed MCTD.

C. Pharmacological management

Management targets the dominant clinical feature at any given time, following eTG Rheumatology, extrapolated EULAR SLE 2023 recommendations, and ARA guidance.

Universal:

• Hydroxychloroquine (HCQ) 200–400 mg/day (≤5 mg/kg ideal body weight) — first-line for nearly all patients with MCTD; reduces flare frequency, modest disease-modifying effect, cardiovascular and lipid co-benefits, pregnancy-compatible. PBS Authority Streamlined. Annual ophthalmology from year five.
• Sun protection SPF50+ — UV triggers SLE-like flares in overlap patients.
• Smoking cessation — accelerates both ILD and cardiovascular disease in MCTD.

For inflammation — arthritis, serositis, skin:

• Prednisolone low-dose maintenance 5–10 mg/day; short courses 20–30 mg for flares; target ≤5 mg/day maintenance per EULAR 2023.
• Methotrexate 7.5–25 mg weekly + folic acid 5 mg the day after — for arthritis, skin, and mild myositis; PBS Authority (RA indication; off-label for MCTD); teratogenic — contraception required and 3-month washout before conception.
• NSAIDs — short-course for arthritis and serositis; caution with renal disease.

For ILD:

• Mycophenolate mofetil (MMF) 1–3 g/day — first-line for ILD, steroid-sparing; PBS Authority; teratogenic — 6-week washout minimum before conception.
• Azathioprine 1–2.5 mg/kg/day — alternative to MMF; check TPMT activity before initiating; pregnancy-compatible. PBS Authority Streamlined.
• Cyclophosphamide IV monthly pulse — severe progressive ILD, refractory cases; specialist-initiated; fertility preservation discussion mandatory.

For PAH:

• PDE5 inhibitors (sildenafil 20 mg three times daily, tadalafil 40 mg daily), endothelin receptor antagonists (bosentan, macitentan), and escalating prostanoid therapy — PBS Section 100 Authority for CTD-PAH, specialist-initiated (respiratory medicine or cardiology); always preceded by right heart catheterisation for haemodynamic confirmation.

For Raynaud’s phenomenon and digital ischaemia:

• Dihydropyridine CCB (nifedipine MR 30–60 mg, amlodipine 5–10 mg) first-line; topical GTN; PDE5 inhibitors for refractory Raynaud’s; IV iloprost for critical ischaemia or digital ulcers.

Cardiovascular risk:

• Treat MCTD as a cardiovascular risk equivalent — aggressive blood pressure, lipid, and glycaemic management. Target LDL below 2.0 mmol/L in established MCTD.

D. Australian operations

MBS items

• Standard consultations — item 23 (Level B); item 36 (Level C, ≥20 min — routine MCTD review); item 44 (Level D, ≥40 min — complex initial or annual surveillance review).
• GPCCMP — item 965 (plan) and item 967 (review), replacing legacy items from 1 July 2025; MCTD universally qualifies as a multisystem chronic disease requiring multidisciplinary care. Opens allied-health sessions: physiotherapy, occupational therapy, dietitian, podiatry, psychology.
• Mental Health Treatment Plan — item 2715/2717 — appropriate for depression, anxiety, fatigue, or illness adjustment that is common in MCTD.
• Investigations — item 11506 (spirometry); item 11512 (DLCO + lung volumes); item 11941 (transthoracic echocardiogram with Doppler); item 56022 (HRCT chest); item 73529 (ANA + ENA panel); item 11700 (ECG).
• Obstetric medicine — item 16401 for high-risk antenatal attendance; item 105/106 for specialist rheumatology, respiratory, cardiology, and nephrology.

PBS

• Hydroxychloroquine 200 mg — Authority Streamlined (rheumatic disease); ≤5 mg/kg IBW; pregnancy-compatible.
• Methotrexate — Authority Required (RA indication; off-label MCTD under rheumatologist supervision); folic acid supplement required; contraception + 3-month washout before conception.
• Mycophenolate mofetil — Authority Required (lupus nephritis + transplant; off-label MCTD-ILD via rheumatology or respiratory physician); teratogenic; 6-week washout.
• Azathioprine 50 mg — Authority Streamlined (autoimmune indication); check TPMT before initiating.
• Cyclophosphamide — Authority (severe autoimmune); specialist-initiated; mesna for haemorrhagic cystitis prophylaxis.
• Sildenafil, tadalafil, bosentan, macitentan — Section 100 Authority for CTD-PAH; specialist-initiated (right heart catheter required).
• Prednisolone, NSAIDs, CCB, ACEi, PPI, statin — PBS general schedule.

Referral pathways

• Rheumatology — every new MCTD diagnosis; routine within 4–6 weeks; same-day for severe active disease.
• Respiratory medicine — any ILD diagnosis or PFT decline; echocardiographic PASP above 40 mmHg.
• Cardiology — right heart catheterisation for confirmed PAH, myocarditis, conduction disease.
• Nephrology — proteinuria plus active urinary sediment, AKI.
• Obstetric medicine / MFM — pre-conception and every MCTD pregnancy.
• Ophthalmology — baseline at HCQ commencement; annual review from year five.

E. Special populations

Pregnancy. MCTD pregnancy is high-risk and requires specialist obstetric medicine co-management. Anti-U1-RNP itself is not teratogenic, but co-existing anti-Ro/SSA antibodies (present in ~30% of MCTD patients) carry a 1–3% risk of irreversible congenital heart block in the infant — foetal echocardiogram at 18–24 weeks is mandatory in anti-Ro/SSA-positive mothers. Disease should be stable for at least six months before conception; hydroxychloroquine and azathioprine are continued through pregnancy; methotrexate and MMF require washout. PAH-MCTD is a relative contraindication to pregnancy given the historically high maternal mortality, and the decision requires individualised discussion with an obstetric medicine specialist and the patient.

Sjögren’s overlap. Dry eyes and dry mouth affect approximately 30% of MCTD patients. Management includes preservative-free artificial tears, salivary stimulants, and six-monthly dental review — sicca-related dental caries accelerates on immunosuppression. Formal Sjögren’s workup (Schirmer test, salivary flow, lip biopsy if needed) helps clarify whether a separate Sjögren’s disease diagnosis applies.

Older adults. The immunosuppression burden in older adults with MCTD requires careful attention to infection prophylaxis, bone health (DXA baseline and every two years if cumulative steroid use), and vaccination — annual inactivated influenza, COVID-19 boosters, pneumococcal PCV20, and Shingrix (zoster subunit vaccine) where eligible. Live vaccines are contraindicated in patients on biologics or high-dose corticosteroids.

Aboriginal and Torres Strait Islander patients. Chronic autoimmune disease carries a high burden in ATSI communities, often compounded by access barriers and late presentation. ATSI health assessments (MBS item 715) facilitate allied-health referral, chronic care coordination, and culturally safe follow-up. Partnership with an Aboriginal health worker or NACCHO-affiliated clinic supports continuity in regional and remote settings.

When to escalate

Refer or escalate when:

• Same day / emergency — rapidly progressive dyspnoea with new hypoxia; right heart failure signs (raised JVP, loud P2, peripheral oedema, syncope); critical digital ischaemia or gangrene; severe proximal muscle weakness with rhabdomyolysis (CK above 5,000 U/L); scleroderma renal crisis (severe hypertension plus AKI); pericardial tamponade.
• Within 4–6 weeks — new MCTD diagnosis for rheumatology review; suspected overlap CTD; pre-conception planning in any patient with MCTD; deterioration on current therapy.
• Respiratory medicine — ILD diagnosis or annual DLCO decline; echocardiographic PASP above 40 mmHg or unexplained dyspnoea.
• Obstetric medicine — as soon as pregnancy is confirmed in any patient with MCTD; ideally pre-conception.

Safety-net language: “If you develop new breathlessness, leg swelling, chest pain, sudden weakness, or difficulty swallowing — contact me the same day.”

What this article is and is not

This is general health information drawn from current Australian clinical guidelines — RACGP, Therapeutic Guidelines (eTG), Australian Rheumatology Association, AMH — and major international evidence including EULAR 2023 SLE recommendations, DETECT 2014, and SLS-II. It is not personal medical advice and does not create a doctor–patient relationship. Specific management decisions, including immunosuppressant choices and surveillance timing, are made with each patient’s GP and treating specialists.

For Australian consumer information: Lupus Foundation Australia · Scleroderma Australia · Arthritis Australia · HealthDirect · Better Health Channel.

For acute concerns: emergency services 000 | Lifeline 13 11 14.

---

Sources cited

1. RACGP — Connective tissue disease in general practice
2. Therapeutic Guidelines (eTG) — Rheumatology: MCTD and overlap syndromes
3. Australian Rheumatology Association
4. Australian Medicines Handbook
5. NPS MedicineWise
6. Alarcón-Segovia and Villarreal — MCTD criteria (J Rheumatol 1989)
7. Mosca et al. — UCTD classification + outcomes (Best Pract Res Clin Rheumatol 2011)
8. Reiseter et al. — MCTD-ILD (Rheumatology 2018)
9. Tani et al. — MCTD long-term outcomes (Autoimmun Rev 2014)
10. Hajas et al. — 30-year MCTD follow-up and PAH mortality (J Rheumatol 2013)
11. Tashkin et al. — SLS-II: MMF vs cyclophosphamide in SSc-ILD (Lancet Respir Med 2016)
12. DETECT — Coghlan et al., PAH screening in CTD (ARD 2014)
13. EULAR 2023 SLE management — Fanouriakis et al. (ARD 2024)
14. Lupus Foundation Australia
15. Scleroderma Australia
16. HealthDirect
17. Better Health Channel